LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Market for qPCR Exceeds USD 3 Billion

By LabMedica International staff writers
Posted on 19 Nov 2014
The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing high quality, reproducible data. It also has many clinical applications including viral detection and quantification, according to Kalorama’s new report. qPCR is considered the gold standard for accurate, sensitive, and fast quantification of nucleic acid sequences. qPCR has been established for a broad range of applications including genotyping, pathogen detection, DNA methylation analysis, and other functions.

PCR is used for testing for the presence of genetic disease mutations. Prospective parents can be tested for being genetic carriers, or their children tested for actually being affected by a disease. DNA samples for prenatal testing can be obtained by amniocentesis, chorionic villus sampling, or even by the analysis of rare fetal cells circulating in the mother's bloodstream. PCR analysis is also essential to preimplantation genetic diagnosis, where individual cells of a developing embryo are tested for mutations.

qPCR is increasingly being used in the medical diagnostic arena for diagnosis of bacterial disease, detection of antibiotic resistance, diagnosis of infectious disease, and quantification of bacterial load. It is also used to detect genetic abnormalities and cancer mutations.

“Many forms of cancer involve alterations to oncogenes,” said Mary Ann Crandall, Kalorama analyst and author of the report. “By using PCR-based tests to study these mutations, therapy regimens can sometimes be individually customized to a patient.”

qPCR-based diagnostic tests are expected to expand in the future. However, these tests will have to meet three requirements: adaptation of existing diagnostic tests, especially according to the discovery of new variants of target genes of specific pathogens, responsible for false-negative results; expansion of diagnostic applications; and lower cost. The benefit is early diagnosis of disease and rapid assessment of resistances to treatment.

The three recognized product types within the qPCR market include reagents, instruments, and software/services. The report, qPCR and dPCR Markets, breaks out the market into these segments, identifies application segments including clinical and research, and reviews companies participating in the market.

Kalorama Information, a division of MarketResearch dot com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services.

Related Links:

Kalorama Information


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more